|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||30.3 (± 3.2) hours|
|Chemical and physical data|
|Molar mass||184.193 g/mol|
|3D model (JSmol)|
Barbital (or barbitone), marketed under the brand names Veronal for the pure acid and Medinal for the sodium salt, was the first commercially available barbiturate. It was used as a sleeping aid (hypnotic) from 1903 until the mid-1950s. The chemical names for barbital are diethylmalonyl urea or diethylbarbituric acid; hence, the sodium salt (known as medinal, a genericised trademark in the United Kingdom) is known also as sodium diethylbarbiturate.
Barbital, then called "veronal", was first synthesized in 1902 by German chemists Emil Fischer and Joseph von Mering, who published their discovery in 1903. Barbital was prepared by condensing diethylmalonic ester with urea in the presence of sodium ethoxide, or by adding at least two molar equivalents of ethyl iodide to the silver salt of malonylurea or possibly to a basic solution of the acid. The result was an odorless, slightly bitter, white crystalline powder.
Its introduction followed the investigations of Fischer and von Merling on the pharmacological properties of certain open and closed Acylureas (then called ureides). Led by the impression that hypnotic action appears to be largely dependent on the presence of ethyl groups, they prepared diethylacetyl urea, diethylmalonyl urea, and dipropylmalonyl urea. All three were found to be hypnotics: the first was about equal in power to the already-known sulphonal (now sulfonmethane), whilst the third was four times as powerful, but its use was attended by prolonged after-effects. Veronal was found to be midway.
Barbital was marketed in 1904 by the Bayer company as “Veronal”. A soluble salt of barbital was marketed by the Schering company as “Medinal.” It was dispensed for “insomnia induced by nervous excitability”.[unreliable source?] It was provided in either crystal form or in cachets (capsules). The therapeutic dose was ten to fifteen grains (0.65-0.97 grams). 3.5 to 4.4 grams is the deadly dose but sleep has also been prolonged up to ten days with recovery.
Barbital was considered to be a great improvement over the existing hypnotics. Its taste was slightly bitter, but better than the strong, unpleasant taste of the commonly used bromides. It had few side effects, and its therapeutic dose was far below the toxic dose. However, prolonged usage resulted in tolerance to the drug, requiring higher doses to reach the desired effect. "I'm literally saturated with it," the Russian tsarina Alexandra Feodeorovna confessed to a friend. Fatal overdoses of this slow-acting hypnotic were not uncommon. Pioneering aviator Arthur Whitten Brown (of "Alcock and Brown" fame) died of an accidental overdose. Japanese writer Ryūnosuke Akutagawa deliberately overdosed on the drug in 1927.
Solutions of sodium barbital have also been used as pH buffers for biological research, e.g., in immunoelectrophoresis or in fixative solutions. As barbital is a controlled substance, barbital-based buffers have largely been replaced by other substances.
- Fischer, Emil; von Mering, Joseph (1903). "Ueber eine neue Klasse von Schlafmitteln". Therapie der Gegenwart. 44: 97–101.
- One or more of the preceding sentences incorporates text from a publication now in the public domain: Chisholm, Hugh, ed. (1911). "Veronal". Encyclopædia Britannica. 27 (11th ed.). Cambridge University Press. p. 1037.
- Finley, Ellingwood (1919). "Veronal". The American Materia Medica, Therapeutics and Pharmacognosy. p. 115. Retrieved 25 July 2015.
- Dehn, Lili The Real Tsaritsa, Boston, Little Brown, 1922, p138
- "Arthur Whitten Brown (1886–1948) – Find A Grave Memorial". Findagrave.com. Retrieved 19 April 2014.
- "Wolf D. Kuhlmann, "Buffer Solutions"" (PDF). 10 September 2006. Retrieved 28 July 2014.
- Steven E. Ruzin (1999). Plant Microtechnique and Microscopy. Oxford University Press. Retrieved 28 July 2014.
- Monthony, JF; Wallace, EG; Allen, DM (Oct 1978). "A non-barbital buffer for immunoelectrophoresis and zone electrophoresis in agarose gels". Clinical Chemistry. 24 (10): 1825–7. PMID 568042.
- (in English) Dombrowski SM, Krishnan R, Witte M, Maitra S, Diesing C, et al. 1998. "Constitutive and barbital-induced expression of the CYP6A2 allele of a high producer strain of CYP6A2 in the genetic background of a low producer strain". Gene 221:69–77.